A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
-
Autoimmune Disorder -
Inflammatory Bowel Disease (IBD) -
Crohn's Disease -
Ulcerative Colitis
For the latest version of this information please go to www.forpatients.roche.com